Promising pancreatic cancer drug study halted before it began
Disease control
Terminated
This study was designed to test a new drug called GFH375 in people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D). The goal was to see if the drug could shrink tumors or slow the disease. However, the study was withdrawn before any participants wer…
Phase: PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC